Differential effects of histone deacetylase inhibitors in tumor and normal cells - What is the toxicological relevance?

Critical Reviews in Toxicology

Volumn 35, Issue 4, 2005, Pages 363-378

  Papeleu, Peggy ^a   Vanhaecke, Tamara ^a   Elaut, Greetje ^a   Vinken, Mathieu ^a   Henkens, Tom ^a   Snykers, Sarah ^a   Rogiers, Vera ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Apoptosis; Differentiation; Hepatoma Cells; Histone Deacetylase Inhibitor; Pharmacotoxicology; Preclinical Drug Development; Primary Hepatocytes; Proliferation; Trichostatin A

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 PHENYLBUTYRIC ACID; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ANTINEOPLASTIC AGENT; APICIDIN; AZELAIC BISHYDROXAMIC ACID; BENZAMIDE; BUTYRIC ACID; CCAAT ENHANCER BINDING PROTEIN; CYCLIC HYDROXAMIC ACID CONTAINING PEPTIDE; CYCLIN D; CYCLIN DEPENDENT KINASE 7; CYCLIN E; CYTOSTATIC AGENT; DEOXYCYTIDINE; DEPSIPEPTIDE; FR 901228; HC TOXIN; HEPATOCYTE NUCLEAR FACTOR 3; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; HYDROXAMIC ACID DERIVATIVE; INDOLE AMIDE HYDROXAMIC ACID; INTERLEUKIN 6; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; PHENYLALANINE DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PYROXAMIDE; SUCCINAMIDE HYDROXAMIC ACID; SULFONAMIDE HYDROXAMIC ACID; TETRAPEPTIDE; TRAPOXIN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RISK; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOSTASIS; DNA DAMAGE; DNA SYNTHESIS; DRUG INHIBITION; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HEPATOMA CELL; HUMAN; LIVER CELL; METASTASIS INHIBITION; MOLECULAR MECHANICS; NONHUMAN; REVIEW; RISK REDUCTION;

ACETYLATION; ANIMALS; CARCINOMA, HEPATOCELLULAR; ENZYME INHIBITORS; HEPATOCYTES; HISTONE DEACETYLASES; HISTONES; HUMANS; NEOPLASMS; TRANSCRIPTION, GENETIC;

ANIMALIA;

EID: 18844407076     PISSN: 10408444     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408440590935639     Document Type: Review

References (213)

1. Studzinski, G.P., and Harrison, L.E. (1999). Differentiation-related changes in the cell cycle traverse. Int. Rev. Cytol. 189:1-58.
2. McLaughlin, F., Finn, P., and La Thangue, N.B. (2003). The cell cycle, chromatin and cancer: Mechanism-based therapeutics come of age. Drug Discov. Today 8:793-802.
3. Dobashi, Y., Takehana, T., and Ooi, A. (2003). Perspectives on cancer therapy: Cell cycle blockers and perturbators. Curr. Med. Chem. 10:2549-2558.
4. Huwe, A., Mazitschek, R., and Giannis, A. (2003). Small molecules as inhibitors of cyclin-dependent kinases. Angew. Chem. Int. Ed. 42:2122-2138.
5. Stewart, Z.A., Westfall, M.D., and Pietenpol, J.A. (2003). Cell cycle dysregulation and anticancer therapy. Trends Pharmacol. Sci. 24:139-145.
6. Vermeulen, K., Van Bockstaele, D.R., and Berneman, Z.N. (2003). The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36:131-149.
7. Lobbezoo, M.W., Krul, M.R., and Pinedo, H.M. (1999). Discovery of new anti-cancer agents. Forum (Geneva) 9(Suppl. 3):47-53.
8. Beeram, M., and Patnaik, A. (2002). Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics. Hematol. Oncol. Clin. North Am. 16:1089-1100.
9. Wade, P.A. (2001). Transcriptional control at regulatory checkpoints by histone deacetylases: Molecular connections between cancer and chromatin. Hum. Mol. Genet. 10:693-698.
10. Workman, J.L., and Kingston, R.E. (1998). Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu. Rev. Biochem. 67:545-579.
11. Kouzarides, T. (1999). Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 9:40-48.
12. Marks, P.A., Rifkind, R.A., Richon, V.M., Breslow, R., Miller, T., and Kelly, W.K. (2001). Histone deacetylases and cancer: Causes and therapy. Nat. Rev. Cancer 1:194-202.
13. Weidle, U.H., and Grossmann, A. (2000). Inhibition of histone deacetylases: A new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res. 20:1471-1485.
14. Liu, L.-T., Chang, H.-C., Chiang, L.-C., and Hung, W.-C. (2003). Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res. 63:3069-3072.
15. Kim, S.H., Ahn, S., Han, J.W., Lee, H.W., Lee, H.Y., Lee, Y.W., Kim, M.R., Kim, K.W., Kim, W.B., and Hong, S. (2004). Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem. Biophys. Res. Commun. 315:964-970.
16. Lee, Y.M., Kim, S.-H., Kim, H.-S., Son, M.J., Nakajima, H., Kwon, H.J., and Kim, K.-W. (2003). Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity. Biochem. Biophys. Res. Commun. 300:241-246.
17. Williams, R.J. (2001). Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin. Invest. Drugs 10:1571-1573.
18. Rössig, L., Li, H., Fisslthaler, B., Urbich, C., Fleming, I., Förstermann, U., Zeiher, A.M., and Dimmeler, S. (2002). Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ. Res. 91:837-844.
19. Kim, M.S., Kwon, H.J., Lee, Y.M., Baek, J.H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H.Y., Kim, C.W., and Kim, K.-W. (2001). Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nature Med. 7:437-443.
20. Sasakawa, Y., Naoe, Y., Takahisa, N., Inoue, T., Sasakawa, T., Matsuo, M., Manda, T., and Mutoh, S. (2003). Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem. Pharmacol. 66:897-906.
21. Sawa, H., Murakami, H., Ohshima, Y., Murakami, M., Yamazaki, I., Tamura, Y., Mima, T., Satone, A., Ide, W., Hashimoto, I., and Karnada, H. (2002). Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol. 19:77-81.
22. Deroanne, C.F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.M., Nusgens, B.V., and Castronovo, V. (2002). Histone deacetylase inhibitors as antiangiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21:427-436.
23. Kim, M.-S., Son, M.-W., Kim, W.-B., Park, Y.I., and Moon, A. (2000). Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. Cancer Lett. 157:23-30.
24. Vigushin, D.M., Ali, S., Pace, P.E., Mirsaidi, N., Ito, K., Adcock, I., and Coombes, R.C. (2001). Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7:971-976.
25. Cohen, L.A., Amin, S., Marks, P.A., Rifkind, R.A., Desai, D., and Richon, V.M. (1999). Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberoylanilohydroxamic acid (SAHA). Anticancer Res. 19:4999-5005.
26. Cohen, L.A., Marks, P.A., Rifkind, R. A., Amin, S., Desai, D., Pittman, B., and Richon, V. M. (2002). Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res. 22:1497-1504.
27. Coffey, D.C., Kutko, M.C., Glick, R.D., Butler, L.M., Heller, H., Rifkind, R.A., Marks, P.A., Richon, V.M., and La Quaglia, M.P. (2001). The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 61:3591-3594.
28. Butler, L.M., Agus, D.B., Sher, H.I., Higgins, B., Rose, A., Cordon-Cardo, C., Thaler, H.T., Rifkind, R.A., Marks, P.A., and Richon, V.M. (2000). Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60:5165-5170.
29. Butler, L.M., Webb, Y., Agus, D.B., Higgins, B., Tolentino, T. R., Kutko, M.C., LaQuaglia, M.P., Drobnjak, M., Cordon-Cardo, C., Scher, H.I., Breslow, R., Richon, V.M., Rifkind, R.A., and Marks, P.A. (2001). Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res. 7:962-970.
30. Richon, V.M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R.A., and Marks, P.A. (1998). A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA 95:3003-3007.
31. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., and Nakanishi, O. (1999). A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96:4592-4597.
32. Sandor, V., Bakke, S., Robey, R.W., Kang, M.H., Blagosklonny, M. V., Bender, J., Brooks, R., Piekarz, R.L., Tucker, E., Figg, W.D., Chan, K.K., Goldspiel, B., Fojo, A.T., Balcerak, S.P., and Bates, S.E. (2002). Phase I clinical trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8:718-728.
33. Gore, S.D., and Garducci, M.A. (2000). Modifying histones to tame cancer: Clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin. Invest. Drugs 9:2923-2934.
34. Phiel, C.J., Zhang, F., Huang, E.Y., Guenther, M.G., Lazar, M.A., and Klein, P.S. (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276:36734-36741.
35. Prakash, S., Foster, B.J., Meyer, M., Wozniak, A., Heilbrun, L. K., Flaherty, L., Zalupski, M., Radulovic, L., Valdivieso, M., and LoRusso, P. M. (2001). Chronic oral administration of CI-994: A phase I study. Invest. New Drugs 19:1-11.
36. Trosko, J.E., and Ruch, R.J. (2002). Gap junctions as targets for cancer chemoprevention and chemotherapy. Curr. Drug Targets 3:465-482.
37. Kmiec, Z. (2001). Cooperation of liver cells in health and disease. Adv. Anat. Embryol. Cell Biol. 161(3-13):1-151.
38. Rogiers, V., Blaauboer, B., Maurel, P., Philips, I.R., and Shephard, E.A. (1995). Hepatocyte-based in vitro models and their application in pharmacotoxicology. Toxicol. In Vitro 9:685-694.
39. Davila, F., and Morris, D.L. (1999). Analysis of cytochrome P450 and phase II conjugating enzyme expression in adult male rat hepatocytes. In Vitro Cell. Dev. Biol. Anim. 35:120-130.
40. Papeleu, P., Elaut, G., Rogiers, V., and Vanhaecke, T. (2002). Cell cultures as in vitro tools for biotransformation studies. In Recent Research Developments in Drug Metabolism and Disposition, Vol. 1, ed. S.G. Pandalai, pp. 199-234. Kerala, India: Transworld Research Network.
41. Loyer, P., Ilyin, G., Cariou, S., Glaise, D., Corlu, A., and Guguen-Guillouzo, C. (1996). Progression through G1 and S phases of adult rat hepatocytes. Prog. Cell Cycle Res. 2:37-47.
42. Strahl, B.D., and Allis, C. D. (2000). The language of covalent histone modifications. Nature 403:41-45.
43. Bradbury, E.M. (1992). Reversible histone modifications and the chromosome cell cycle. BioEssays 14:9-16.
44. Allfrey, V., Faulkner, R.M., and Mirsky, A.E. (1964). Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl. Acad. Sci. USA 51:786-794.
45. Loidl, P. (1994). Histone acetylation: Facts and questions. Chromosoma 103:441-449.
46. Wolfe, A.P. (1997). Sinful repression. Nature 387:16-17.
47. Lopez-Rodas, G., Brosch, G., Georgieva, E.I., Sendra, R., Franco, L., and Loidl, P. (1993). Histone deacetylase - A key enzyme for the binding of regulatory proteins to chromatin. FEBS Lett. 317:175-180.
48. De Ruijter, A.J.M, van Gennip, A.H., Caron, H.N., Kemp, S., and Kuilenburg, A.B.P. (2003). Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem. J. 370:737-749.
49. Gu, W., and Roeder, R.G. (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606.
50. Boyes, J., Byfield, P., Nakatami, Y., and Ogryzko, V. (1998). Regulation of activity of the transcription factor GATA-1 by acetylation. Nature (Lond.) 396:594-598.
51. Jin, S., and Scotto, K.W. (1998). Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell Biol. 18:4377-4384.
52. Imhof, A., Yang, Y.J., Ogryzko, V.V., Nakatani, Y., Wolffe, A.P., and Ge, H. (1997). Acetylation of general transcription factors by histone acetyltransferases. Curr. Biol. 7:689-692.
53. Munshi, N., Merika, M., Yie, J., Senger, K., Chen, G., and Thanos, D. (1998). Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Mol. Cell 2:457-467.
54. Roth, S.Y., Denu, J.M., and Allis, C.D. (2001). Histone acetyltransferases. Annu. Rev. Biochem. 70:81-120.
55. Lechner, T., Lusser, A., Brosch, G., Eberharter, A., Goralik-Schramel, M., and Loidl, P. (1996). A comparative study of histone deacetylases in plant, fungal and vertebrate cells. Biochim. Biophys.Acta 1296:191-198.
56. Taunton, J., Hassig, C.A., and Schreiber, S.L. (1996). A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272:408-411.
57. Yang, W.-M., Yao, Y.L., Sun, J.M., Davie, J.R., and Seto, E. (1997). Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J. Biol. Chem. 272:28001-28007.
58. Dangond, F., Hafler, D.A., Tong, J.K., Randall, J., Kojima, R., Utku, N., and Gullans, S.R. (1998). Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells. Biochem. Biophys. Res. Commun. 242:648-652.
59. Emiliani, S., Fischle, W., Van Lint, C., Al-Abed, Y., and Verdin, E. (1998). Characterization of a human RPD3 ortholog, HDAC3. Proc. Natl. Acad. Sci. USA 95:2795-2800.
60. Buggy, J.J., Sideris, M.L., Mak, P., Lorimer, D.D., McIntosh, B., and Clark, J.M. (2000). Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem. J. 350:199-205.
61. Van den Wyngaert, I., de Vries, W., Kremer, A., Neefs, J., Verhasselt, P., Luyten, W.H., and Kass, S.U. (2000). Cloning and characterization of human histone deacetylase 8. FEBS Lett. 478:77-83.
62. Gray, S.G., and Ekström, T.J. (2001). The human histone deacetylase family. Exp. Cell Res. 262:75-83.
63. Gao, L., Cueto, M.A., Asselbergs, F., and Atadja, P. (2002). Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277:25748-25755.
64. Cress, W.D., and Seto, E. (2000). Histone deacetylases, transcriptional control and cancer. J. Cell Physiol. 184:1-16.
65. Ng, H.H., and Bird, A. (2000). Histone deacetylases: Silencers for hire. Trends Biochem. Sci. 25:121-126.
66. Wen, Y.D., Perissi, V., Staszewski, L.M., Yang, W.M., Krones, A., Glass, C.K., Rosenfeld, M.G., and Seto, E. (2000). The histone deacetylase 3 complex contains nuclear receptor corepressors. Proc. Natl. Acad. Sci. USA 97:7202-7207.
67. Li, J., Wang, J., Nawaz, Z., Liu, J.M., Qin, J., and Wong, J. (2000). Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 19:4342-4350.
68. Dangond, F., Hendriksson, M., Zardo, G., Caiafa, P., Ekström, T.J., and Gray, S.G. (2001). Differential expression of class I HDACs: Roles of cell density andcell cycle. Int. J. Oncol. 19:773-777.
69. Fischle, W., Emiliani, S., Hendzel, M.J., Nagase, T., Nomura, N., Voelter, W., and Verdin, E. (1999). A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. J. Biol. Chem. 274:11713-11720.
70. Fischle, W., Kiermer, V., Dequiedt, F., and Verdin, E. (2001). The emerging role of class II histone deacetylase. Biochem. Cell Biol. 79:337-348.
71. Wang, A.H., Bertos, N.R., Vezmar, M., Pelletier, N., Crosato, M., Heng, H.H., Th'ng, J., Han, J., and Yang, X.J. (1999). HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol. Cell. Biol. 19:7816-7827.
72. Miska, E.A., Karlsson, C., Langley, E., Nielsen, S.J., Pines, J., and Kouzarides, T. (1999). HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J. 18:5099-5107.
73. Grozinger, C.M., Hassig, C.A., and Schreiber, S.L. (1999). Three proteins define a class of human histone deacetylases related to yeast Hdalp. Proc. Natl. Acad. Sci. USA 96:4868-4873.
74. Bjerling, P., Silverstein, R.A., Thon, G., Caudy, A., Grewal, S., and Ekwall, K. (2002). Functional divergence between histone deacetylases in fission yeast by distinct cellular localization and in vivo specificity. Mol. Cell Biol. 22:2170-2181.
75. Petrie, K., Guidez, F., Howell, L., Healy, L., Waxman, S., Greaves, M., and Zelent, A. (2003). The histone deacetylase 9 gene encodes multiple protein isoforms. J. Biol. Chem. 278:16059-16072.
76. Frye, R.A. (1999). Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem. Biophys. Res. Commun. 260:273-279.
77. Landry, J., Sutton, A., Tafrov, S.T., Heller, R.C., Ctebbins, J., Pillus, L., and Sternglanz, R. (2000). The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc. Natl. Acad. Sci. USA 97:5807-5811.
78. Frye, R.A. (2000). Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273:793-798.
79. Zhang, Y., Ng, H.H., Erdjument-Bromage, H., Tempst, P., Bird, A., and Reinberg, D. (1999). Analysis of NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13:1924-1935.
80. Marks, P.A., Miller, T., and Richon, V.M. (2003). Histone deacetylases. Curr. Opin. Pharmacol. 3:344-351.
81. Meinke, P.T., and Liberator, P. (2001). Histone deacetylase: A target for antiproliferative and antiprotozoal agents. Curr. Med. Chem. 8:211-235.
82. Warrell, R.P., He, L.Z., Richon, V.M., Calleja, E., and Pandolfi, P.P. (1998) Therapeutic targeting of transcription in acute myelocytic leukemia. JNCI 90:1621-1625.
83. Göttlicher, M., Minucci, S., Zhu, P., Krämer, O.H., Schimpf, A., Giavara, S., Sleeman, J.P., Lo Coco, F., Nervi, C., Pelicci, P.G., and Heinzel, T. (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20:6969-6978.
84. 2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J. Med. Chem, 47:467-474.
85. Tsuji, N., Kobayashi, N., Nagashima, K., Wakisaki, Y., and Koizumi, K. (1976). A new fungal antibiotic, trichostatin. J. Antibiot. 29:1-6.
86. Komatsu, Y., Tomizaki, K.Y., Tsukamoto, M., Kato, T., Nishino, N., Sato, S., Yamori, T., Tsuruo, T., Furumai, R., Yoshida, M., Horinouchi, S., and Hayashi, H. (2001). Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res. 61:4459-4466.
87. Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., and Horinouchi, S. (2001). Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA 98:87-92.
88. Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S., and Beppu, T. (1993). Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 268:22429-22435.
89. Darkin-Rattray, S.J., Gurnett, A.M., Myers, R.W., Dulski, P.M., Crumley, T.M., Allocco, J.J., Cannova, C., Meinke, P.T., Colletti, S.L., Bednarek, M.A., Singh, S.B., Goetz, M.A., Dombrowski, A.W., Polishook, J.D., and Schmatz, D.M. (1996). Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA 93:13143-13147.
90. Sambucetti, L.C., Fischer, D.D., Zabludoff, S., Kwon, P.O., Chamberlin, H., Trogani, N., Xu, H., and Cohen, D. (1999). Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274:34940-34947.
91. Han, J.W., Ahn, S.H., Park, S.H., Wang, S.Y., Bae, G.U., Seo, D.W., Kwon, H.K., Hong, S., Lee, H.Y., Lee, Y.W., and Lee, H.W. (2000). Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. 60:6068-6074.
92. Sasakawa, Y., Naoe, Y., Inoue, T., Sasakawa, T., Matsuo, M., Manda, T., and Mutoh, S. (2002). Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem. Pharmacol. 64:1079-1090.
93. Lee, B.I., Park, S.H., Kim, J.W., Sausville, E.A., Kim, H.T., Nakanishi, O., Trepel, J.B., and Kim, S.J. (2001). MS-275, a histone deacetylase inhibitor, selectively induced transforming growth factor β type II receptor expression in human breast cancer cells. Cancer Res. 91:931-934.
94. Su, G.H., Sohn, T.A., Ryu, B., and Kern, S.E. (2000). A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 60:3137-3142.
95. Sonoda, H., Nishida, K., Yoshioka, T., Ohtani, M., and Sugita, K. (1996). Oxamflatin: A novel compound which reverses malignant phenotype to normal one via induction of junD. Oncogene 13:143-149.
96. Jung, M., Brosch, G., Kolle, D., Scherf, H.,Gerhauser, C., and Loidl, P. (1999). Amide analogues of trichostatin A as inhibitors of hi stone deacetylase and inducers of terminal cell differentiation. J. Med. Chem. 8:1505-1511.
97. Van Ommeslaeghe, K., Elaut, G., Brecx, V., Papeleu, P., Iterbeke, K., Geerlings, P., Tourwé, D., and Rogiers, V. (2003). Amide analogues of TSA: Synthesis, binding mode analysis and HDAC inhibition. Bioorg. Med. Chem. Lett. 13:1861-1864.
98. Catley, L., Weisberg, E., Tai, Y.-T., Atadja, P., Remiszewski, S., Hideshima, T., Mitsiades, N., Shringarpure, E., LeBlanc, R., Chauhan, D., Munshi, N.C., Schlossman, R., Richardson, P., Griffin, J., and Anderson, K.C. (2003). NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102:2615-2622.
99. Plumb, J.A., Finn, P.W., Williams, R.J., Bandara, M.J., Romero, M.R., Watkins, C.J., La Thangue, N.D., and Brown, R. (2003). Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor, PXD101. Mol. Cancer Ther. 2:721-728.
100. Dai, Y., Guo, Y., Guo, J., Pease, L.J., Li, J., Marcotte, P.A., Glaser, K.B., Tapang, P., Albert, D.H., Richardson, P.L., Davidsen, S.K., and Michaelides, M.R. (2003). Indole amide hydroxamic acids as potent inhibitors of histone deacetylases. Bioorg. Med. Chem. Lett. 13:1897-1901.
101. Dai, Y., Guo, Y., Curtin, M.L., Li, J., Pease, L.J., Guo, J., Marcotte, P.A., Glaser, K.B., Davidsen, S.K., and Michaelides, M.R. (2003). A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg. Med. Chem. Lett. 13:3817-3820.
102. Lavoie, R., Bouchain, G., Frechette, S., Woo, S.H., Khalil, E.A., Leit, S., Fournel, M., Yan, P.T., Trachy-Bourget, M.-C., Beaulieu, C., Li, Z., Besterman, J., and Delorme, D. (2001). Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 11:2847-2850.
103. Ohtani, M., Matsuura, T., Shirase, K., and Sugita, K. (1996). (2E)-5-[3-[Phenylsulfonyl)amino]phenyl]-pent-2-en-4-ynohydroxamic acid and its derivatives as novel and potent inhibitors of ras transformation. J. Med. Chem. 39:2871-2873.
104. Wittich, S., Scherf, H., Xie, C., Brosch, G., Loidl, P., Gerhäuser, C., and Jung, M. (2002). Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: In vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. J. Med. Chem. 45:3296-3309.
105. Massa, S., Mai, A., Sbardella, G., Esposito, M., Ragno, R., Loidl, P., and Brosch, G. (2001). 3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. J. Med. Chem. 44:2069-2072.
106. Curtin, M.L., Garland, R.B., Heyman, R., Frey, R.R., Michaelides, M.R., Li, L., Pease, L.J., Glaser, K.B., Marcotte, P.A., and Davidsen, S.K. (2002). Succinimide hydroxamic acids as potent inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett. 12:2919-2923.
107. Skarpidi, E., Cao, H., Heltweg, V., White, B.F., Marhenke, R.L., Jung, M., and Stammatoyannopoulos, G. (2003). Hydroxamide derivatives of short-chain fatty acids are potent inducers of human fetal globin gene expression. Exp. Haematol. 31:197-203.
108. Butler, L.M., Zhou, X., Xu, W.S., Sher, H.I., Rifkind, R.A., Marks, P.A., and Richon, V.M. (2002). The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2 and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA 99:11700-11705.
109. Frey, R.R., Wada, C.K., Garland, R.B., Curtin, M.L., Michaelides, M.R., Li, J., Pease, L.J., Glaser, K.B., Marcotte, P.A., Bouska, J.J., Murphy, S.S., and Davidsen, S.K. (2002). Trifluoromethylketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett. 12:3443-3447.
110. Finnin, M.S., Donigian, J.R., Cohen, A., Richon, V.M., Rifkind, R.A., Marks, P.A., Breslow, R., and Pavletich, N.P. (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-193.
111. Qiu, L., Burgess, A., Fairlie, D.P., Leonard, H., Parsons, P.G., and Gabrielli, B.G. (2000). Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol. Cell 11:2069-2083.
112. Kouraklis, G., and Theocharis, S. (2002). Histone deacetylase inhibitors and anticancer therapy. Curr. Med. Chem. 2:477-4484.
113. Kim, D.H., Kim, M., and Kwon, H.J. (2003). Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J. Biochem. Mol. Biol. 36:110-119.
114. Papeleu, P., Loyer, P., Vanhaecke, T., Elaut, G., Geerts, A., Guguen-Guillouzo, C., and Rogiers, V. (2003). Trichostatin A induces differential cell cycle arrests but does not induce apoptosis in primary cultures of mitogen-stimulated rat hepatocytes. J. Hepatol. 39:374-382.
115. Herold, C., Ganslmayer, M., Ocker, M., Hermann, M., Geerts, A., Hahn, E.G., and Schuppan, D. (2002). The histone deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J. Hepatol. 36:233-240.
116. Yamashita, Y., Shimada, M., Harimoto, N., Rikimaru, T., Shirabe, K., Tanaka, S., and Sugimachi, K. (2003). Histone deacetylase inhibitor trichostatin A induces cell cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int. J. Cancer 103:572-576.
117. Gray, S.G., and Ekström, T.J. (1998). Effects of cell density and trichostatin A on the expression of HDAC1 and p57Kip2 in Hep3B cells. Biochem. Biophys. Res. Commun. 245:423-427.
118. Loyer, P., Glaise, D., Cariou, S., Baffet, G., Meijer, L., and Guguen-Guillouzo, C. (1994). Expression and activation of cdks (1 and 2) and cyclins in the cell cycle progression during liver regeneration. J. Biol. Chem. 269:2491-2500.
119. Sowa, Y., Orita, T., Minamikawa, S., Nakano, K., Mizuno, T., Nomura, H., and Sakai, T. (1997). Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem. Biophys. Res. Commun. 241:142-150.
120. Archer, S.Y., Meng, S., Shei, A., and Hodin, R.A. (1998). p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA 95:6791-6796.
121. Sandor, V., Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M.V., and Bates, S.E. (2000). p21-dependent G1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br. J. Cancer 83:817-825.
122. WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97:10014-10019.
123. Huang, L., Sowa, Y., Sakai, T., and Pardee, A.B. (2000). Activation of the p21 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19:5712-5719.
124. Glaser, K.B., Staver, M.J., Waring, J.F., Stender, J., Ulrich, R.G., and Davidsen, S.K. (2003). Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2:151-163.
125. Wharton, W., Savell, J., Cress, W.D., Seto, E., and Pledger, W.J. (2000). Inhibition of mitogenesis in Balb/c-3T3 cells by Trichostatin A. Multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes. J. Biol. Chem. 275:33981-33987.
126. Boutillier, A.-L., Trinh, E., and Loeffler, J.-P. (2003). Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J. Neurochem. 84:814-828.
127. Van Lint, C., Emiliani, S., and Verdin, E. (1996). The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Exp. 5:245-253.
128. Mariadson, J., Corner, G., and Augenlicht, L. (2000). Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: Comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 60:4561-4572.
129. Lee, H., Lee, S., Baek, M., Kim, H.-Y., and Jeoung, D.-I. (2002). Expression profile analysis of trichostatin A in human gastric cancer cells. Biotech. Lett. 24:377-381.
130. Vanhaecke, T., Henkens, T., Kass, G., and Rogiers, V. (2004). Effect of the histone deacetylase inhibitor Trichostatin A on spontaneous apoptosis in various adult rat hepatocyte cultures. Biochem. Pharmacol. 68:753-760.
131. De Smet, K., Loyer, P., Gilot, D., Vercruysse, A., Guguen-Guillouzo, C., and Rogiers, V. (2001). Effects of epidermal growth factor on CYP inducibility by xenobiotics, DNA replication, and caspase activations in collagen I gel sandwich cultures of rat hepatocytes. Biochem. Pharmacol. 61:1293-1303.
132. Hayashi, Y., Wang, W., Ninomiya, T., Nagano, H., Ohta, K., and Itoh, H. (1999). Liver-enriched transcription factors and differentiation of hepatocellular carcinoma. J. Clin. Pathol. Mol. Pathol. 52:19-24.
133. Schrem, H., Klempnauer, J., and Borlak, J. (2002) Liver-enriched transcription factors in liver function and development. Part 1: The hepatocyte nuclear factor network and liver-specific gene expression. Pharmacol. Rev. 54:129-158.
134. Watt, A.J., Garrison, W.D., and Duncan, S.A. (2003). HNF4: A central regulator of hepatocyte differentiation and function. Hepatology 37:1249-1253.
135. Soutoglou, E., Katrakili, N., and Talianidis, I. (2000). Acetylation regulates transcription factor activity at multiple levels. Mol. Cell 5:745-751.
136. Soutoglou, E., Papafotiou, G., Katrakili, N., and Talianidis, I. (2000). Transcriptional activation by hepatocyte nuclear factor-1 requires synergism between multiple coactivator proteins. J. Biol. Chem. 275:12515-12520.
137. Zvibel, I., Fiorino, A.S., Shlomo, B., and Lola, M.R. (1998). Phenotypic characterization of rat hepatoma cell lines and lineage-specific regulation of gene expression by differentiation agents. Differentiation 63:215-223.
138. Xu, L., Ruh, T.S., and Ruh, M.R (1997). Effect of the histone deacetylase inhibitor Trichostatin A on the responsiveness of rat hepatocytes to dioxin. Biochem. Pharmacol. 53:951-957.
139. Li, J., Ning, G., and Duncan, S.A. (2000). Mammalian hepatocyte differentiation requires the transcription factor HNF-4α. Genes Dev. 14:464-474.
140. Hsiang, C.H., Marten, N.W., and Straus, D.S. (1999). Upstream region of rat serum albumin gene promoter contributes to promoter activity: Presence of functional binding site for hepatocyte nuclear factor-3. Biochem. J. 338:241-249.
141. Xanthopoulos, K.G., Prezioso, V.R., Chen, W.S., Sladek, F.M., Cortese, F.M., Cortese, R., and Darnell, J.E., Jr. (1991). The different tissue transcription patterns of genes for HNF-1, C[EBP, HNF-3 and HNF-4, protein factors that govern liver-specific transcription. Proc. Natl. Acad. Sci. USA 88:3807-3811.
142. Parsons, P.G., Hansen, C., Fairlie, D.P., West, M.L., Danoy, P.A.C., Sturm, R.A., Dunn, I.S., Pedley, J., and Ablett, E.M. (1997). Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Biochem. Pharmacol. 53:1719-1724.
143. Weiser, T.S., Guo, Z.S., Ohnmacht, G.A., Parkhurst, M.L., Tong-On, P., Marincola, F.M., Fischette, M.R., Yu, X., Chen, G.A., Hong, J.A., Stewart, J.H., Nguyen, D.M., Rosenberg, S.A., and Schrump, D.S. (2001). Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J. Immunother. 24:151-161.
144. Ailenberg, M., and Silverman, M. (2003). Differential effects of trichostatin A on gelatinase A expression in 3T3 fibroblasts and HT-1080 fibrosarcoma cells: Implications for use of TSA in cancer therapy. Biochem. Biophys. Res. Commun. 302:181-185.
145. Henderson, C., Mizzau, M., Paroni, G., Maestro, R., Schneider, C., and Brancolini, C. (2003). Role of caspases, Bid and p53 in the apoptotic response triggered by histone deacetylase inhibitors TSA and SAHA. J. Biol. Chem. 278:12579-12589.
146. Saunders, N., Dicker, A., Popa, C., Jones, S., and Dahler, A. (1999). Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res. 59:399-404.
147. El-Deiry, W.S. (1998). p21/p53, cellular growth control and genomic integrity. Curr. Top. Microbiol. Immunol. 227:121-137.
148. Gorospe, M., Wang, X., Guyton, K.Z., and Holbrook, N.J. (1996). Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells. Mol. Cell. Biol. 16:6654-6660.
149. Gorospe, M., Cirielli, C., Wang, X., Seth, P., Capogrossi, M.C., and Holbrook, N.J. (1997). p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene 14:929-935.
150. WAF1 protein. J. Biol. Chem. 278:21221-21231.
151. Wang, J., and Walsh, K. (1996). Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273:359-361.
152. Polyak, K., Waldman, T., He, T.C., Kinzler, K.W., and Vogelstein, B. (1996). Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10:1945-1952.
153. Iwao, K., and Tsukamoto, I. (1999). Quercetin inhibited DNA synthesis and induced apoptosis associated with increase in c-fos mRNA level and the upregulation of p21WAF1CIP1 mRNA and protein expression during liver regeneration after partial hepatectomy. Biochim. Biophys. Acta 1427:112-120.
154. Kobayashi, K., and Tsukamoto, I. (2001). Prolonged Jun N-terminal (JNK) activation and the upregulation of p53 and p21 preceded apoptosis in hepatocytes after partial hepatectomy and cisplatin. Biochim. Biophys. Acta 1537:79-88.
155. Papakyriakou, P., Tzardi, M., Valatas, V., Kanavaros, P., Karydi, E., Notas, G., Xidakis, C., and Kouroumalis, E. (2002). Apoptosis and apoptosis related proteins in chronic viral liver disease. Apoptosis 7:133-141.
156. Qiao, L., McKinstry, R., Gupta, S., Gilfor, D., Windle, J.J., Hyemon, P.B., Grant, S., Fisher, P.B., and Dent, P. (2002). Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53. Hepatology 36:39-48.
157. Meikrantz, W., and Schlegel, R. (1995). Apoptosis and the cell cycle. J. Cell. Biochem. 58:160-174.
158. Xaus, J., Cardo, M., Valledor, A.F., Soler, C., Lloberas, J., and Celada, A. (1999). Interferon gamma induces the expression of p21waf-1 and arrests macrophage cell cycle, preventing induction of apoptosis. Immunity 11:103-113.
159. Gilbert, S., Loranger, A., Daigle, N., and Marceau, N. (2001). Simple keratins 8 and 18 provide resistance to Fas-mediated apoptosis. The protection occurs through a receptor-targetting modulation. J. Cell. Biol. 154:763-773.
160. Sheahan, S., Bellamy, C.O.C., Treanor, L., Harrison, D.J., and Prost, S. (2004). Additive effects of p53, p21 and Rb deletion in triple knockout primary hepatocytes. Oncogene 23:1489-1497.
161. Guidotti, J.-E., Brégerie, O., Robert, A., Debey, P., Brechot, C., and Desdouets, C. (2003). Liver cell polyploidization: A pivotal role for binuclear hepatocytes. J. Biol. Chem. 278:19095-19101.
162. Lamboley, C., Bringuier, A.-F., and Feldmann, G. (2000). Induction of apoptosis in normal cultured rat hepatocytes and in Hep3B, a human hepatoma cell line. Cell Biol. Toxicol. 16:185-200.
163. Williams, G.M., and Iatropoulos, M.J. (2002). Alteration of liver cell function and proliferation: Differentiation between adaptation and toxicity. Toxicol. Pathol. 30:41-53.
164. Casciano, D.A. (2000). Development and utilization of primary hepatocyte culture systems to evaluate metabolism, DNA binding and DNA repair of xenobiotics. Drug Metab. Rev. 32:1-13.
165. O'Connor, P.J., Manning, F.C.R., Gordon, A.T., Billet, M.A., Cooper, D.P., Elder, R.H., and Margison, G.P. (2000). DNA repair: Kinetics and thresholds. Toxicol. Pathol. 28:375-381.
166. Saeter, G., Schwarze, P.E., Nesland, J.M., Juul, N., Pettersen, E.O., and Seglen, P.O. (1988). The polyploidization growth pattern of normal rat liver is replaced by divisional diploid growth in hepatocellular nodules and carcinomas. Carcinogenesis 9:939-945.
167. Seglen, P.O. (1997). DNA ploidy and autophagic protein degradation as determinants of hepatocellular growth and survival. Cell Biol. Toxicol. 13:301-315.
168. Ankoma-Sey, V. (1999) Hepatic regeneration-Revisiting the myth of Prometheus. News Physiol. Sci. 14:149-155,
169. Taub, R. (1996). Transcriptional control of liver regeneration. FASEB J. 10:413-427.
170. Michalopoulos, G.K., and DeFrances, O. (1997). Liver regeneration. Science 276:60-66.
171. Etienne, P.L., Baffet, G., Desvergne, B., Boisnard-Rissel, M., Glaise, D., and Guguen-Guillouzo, C. (1988). Transient expression of c-fos and constant expression of c-myc in freshly isolated and cultured normal adult rat hepatocytes. Oncogene Res. 3:255-262.
172. Loyer, P., Cariou, S., Glaise, D., Bilodeau, M., Baffet, G., and Guguen-Guillouzo, C. (1996). Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. J. Biol. Chem. 271:11484-11492.
173. Sherr, C.J. (1993). Mammalian G1 cyclins. Cell 73:1059-1065.
174. Sherr, C.J. (1994). G1 phase progression: Cycling on cue. Cell 79:551-555.
175. Walker, D.H., and Maller, J.L. (1991). Role for cyclin A in the dependence of mitosis on completion of DNA replication. Nature 354:314-317.
176. Arrellano, M., and Moreno, S. (1997). Regulation of CDK/cyclin complexes during the cell cycle. Int. J. Biochem. Cell Biol. 29:559-573.
177. King, R.W., Jackson, P.K., and Kirschner, M.W. (1994). Mitosis in transition. Cell 79:563-571.
178. Hartwell, L.H. (1992). Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543-546.
179. Hartwell, L.H., and Weinert, T.A. (1989). Checkpoints: Controls that ensure the order of cell cycle events. Science 246:629-634.
180. Magnaghi-Jaulin, L., Ait-Si-Ali, S., and Harel-Bellan, A. (1999). Histone acetylation in signal transduction by regulatory signals. Sem. Cell Dev. Biol. 10:197-203.
181. Roberts, J.M., Koff, A., Polyak, K., Firpo, E., Collins, S., Ohtsubo, M., and Massagué, J. (1994). Cyclins, cdks and cyclin kinase inhibitors. Cold Spring Harbor Symp. Quant. Biol. 59:31-38.
182. Brehm, A., and Kouzarides, T. (1999). Retinoblastoma proteins meets chromatin. TIBS 24:142-145.
183. Sherr, C.J., and Roberts, J.M. (1999). CDK inhibitors: Positive and negative regulators of G1 phase progression. Genes Dev. 13:1501-1512.
184. del Olmo, J.A., Serra, M.A., Rodriguez, F., Escudero, A., Gilabert, S., and Rodrigo, J.M. (1998). Incidence and risk factors for hepatocellular carcinoma in 967 patients with cirrhosis. J. Cancer Res. Clin. Oncol. 124:560-564.
185. Kountouras, J., Zavos, C., and Chatzopoulos, D. (2003). Apoptosis in hepatocellular carcinoma. Hepatogastroenterology 50:242-249.
186. Hui, A.M., Makuuchi, M., and Li, X. (1998). Cell cycle regulators and human hepatocarcinogenesis. Hepato-Gastroenterology 45:1635-1642.
187. Murakami, Y., Hayashi, K., Hirohashi, S. and Sekiya, T. (1991). Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 51:5520-5525.
188. Hsu, I.C., Tokiwa, T., Bennett, W., Metcalf, R.A., Welsh, J.A., Sun, T., and Harris, C.C. (1993). p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 14:987-992.
189. Nhieu, J.T., Renard, C.A., Wei, Y., Cherqui, D., Zafrani, E.S., and Buenida, M.A. (1999). Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am. J. Pathol. 155:703-710.
190. Nishida, N., Fukuda, Y., Ishizaki, K., and Nakao, K. (1997). Alteration of cell cycle-related genes in hepatocarcinogenesis. Histol. Histopathol. 12:1019-1025.
191. Yamasaki, H., Krutovskikh, V., Mesnil, M., Columbano, A., Tsuda, H., and Ito, N. (1993) Gap junctional intercellular communication and cell proliferation during rat liver carcinogenesis. Environ. Health Perspect. 101(Suppl. 5):191-197.
192. Neveu, M.J., Hully, J.R., Babcock, K.L., Hertzberg, E.L., Nicholson, B.J., Paul, D.L., and Pilot, H.C. (1994). Multiple mechanisms are responsible for altered expression of gap junction genes during oncogenesis in rat liver. J. Cell Sci. 107:83-95.
193. Peng, S.Y., Lai, P.L., and Hsu, H.C. (1993). Amplification of the c-myc gene in human hepatocellular carcinoma: Biological significance. J. Formos. Med. Assoc. 92:866-870.
194. Nishida, N., Fukuda, Y., Komeda, T., Kita, R., Sando, T., Furukawa, M., Amenomori, M., Shibagaki, I., Nakao, K., and Ikenaga, M. (1994). Amplification and overexpression of cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 54:3107-3110.
195. Rabbitts, T.H. (1994). Chromosomal translocations in human cancer. Nature 372:143-149.
196. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. (1991). p53 mutations in human cancers. Science 253:49-53.
197. Greenblatt, M.S., Bennett, W.P., Hollstein, M., and Harris, C.C. (1994). Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878.
198. Hui, A.M., Kanai, Y., Sakamoto, M., Tsuda, H., and Hirohashi, S. (1997). Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas. Hepatology 25:575-579.
199. Burgess, A.J., Pavey, S., Warrener, R., Hunter, L.J., Piva, T.J., Musgrove, E.A., Saunders, N., Parsons, P.O., and Gabrielli, B.G. (2001). Upregulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol. 60:828-837.
200. Maslansky, C.J., and Williams, G.M. (1985). Ultraviolet light-induced DNA repair synthesis in hepatocytes from species of differing longevities. Mech Ageing Dev. 29:191-203.
201. Tong, C., Fazio, M., and Williams, G.M. (1980). Cell cycle-specific mutagenesis at the hypoxanthine phosphoribosyltransferase locus in adult rat liver epithelial cells. Proc. Natl. Acad. Sci. USA 77:7377-7379.
202. Jover, R., Bort, R., Goméz-Lechon, M.J., and Castell, J.V. (1998). Reexpression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett 431:227-230.
203. Flodby, P., Liao, D.Z., Blanck, A., Xanthopoulos, K.G., and Hallstrom, I.P. (1995). Expression of the liver-enriched transcription factors C/EBP alpha, C/EBP beta, HNF-1 and HNF-4 in preneoplastic nodules and hepatocellular carcinoma in rat liver. Mol. Carcinogen. 12:103-109.
204. Tomizawa, M., Wang, Y.Q., Ebara, M., Saisho, H., Watanabe, K., Nakagawa, A., and Tagawa, M. (2002). Decreased expression of the CCAAT/enhancer binding protein alpha gene involved in hepatocyte proliferation in human hepatocellular carcinomas. Int. J. Mol. Med. 9:597-600.
205. Elaut, G., Török, G., Vinken, M., Laus, G., Papeleu, P., Tourwé, D., and Rogiers, V. (2002). Major phase I biotransformation pathways of trichostatin A in rat hepatocytes and in rat and human liver microsomes. Drug Metab. Dispos. 30:1320-1328.
206. Schilsky, R.L. (2002). End points in cancer clinical trials and the drug approval process. Clin. Cancer Res. 8:935-938.
207. Boelsterli, U.A. (2003). Mechanistic Toxicology: The Molecular Basis of How Chemicals Disrupt Biological Targets. New York: Taylor Francis.
208. Thiagalingam, S., Cheng, K.H., Lee, H.J., Mineva, N., Thiagalingam, A., and Ponte, J.F. (2003). Histone deacetylase: Unique players in shaping the epigenetic histone code. Ann. NY Acad. Sci. 983:84-100.
209. Jose, B., Okamura, S., Kato, T., Nishino, N., Sumida, Y., and Yoshida, M. (2004). Toward an HDAC6 inhibitor: Synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from α-tubulin sequence. Bioorg. Med. Chem. 12:1351-1356.
210. Glaser, K.B., Li, J., Staver, M.J., Wei, R.-Q., Albert, D.H., and Davidsen, S.K. (2003). Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 310:529-536.
211. Yoshida, M., Furumai, R., Nishiyama, M., Komatsu, Y., Nishino, N., and Horinouchi, S. (2001). Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 48:S20-S26.
212. Kumar, G.N., and Surapaneni, S. (2001). Role of drug metabolism in drug discovery and development. Med. Res. Rev. 21:397-411.
213. Pritchard, J.F., Jurima-Romet, M., Reimer, M.L.J., Mortimer, E., Rolfe, B. and Cayen, M.N. (2003). Making better drugs: Decision gates in non-clinical drug development. Nat. Rev. Drug Discov. 2:542-553.